spacer
home > epc > summer 2002 > in silico proteomics - evolution of bioinformatics into biomagic
PUBLICATIONS
European Pharmaceutical Contractor

In Silico Proteomics - Evolution of Bioinformatics into Biomagic

'Any technology sufficiently advanced is indistinguishable from magic' -
Arthur C. Clarke, Third Law of Technology
'Any magic sufficiently reliable is indistinguishable from technology' -
Corollary

Moving from data to knowledge is a new frontier for drug discovery. But why do we need to make the change and how can we do it?

The history of drug discovery over the last decade has been one of spiralling expense with investment in sophisticated platform technologies spectacularly failing to lead to an increase in new drugs (see Figure 1). The investments in combinatorial chemistry and genomics were expected to deliver a wealth of new targets and new chemical entities (NCEs).

This expectation was driven by two main factors. The first was the insightful declaration that a US$300 billion a year industry was founded on drugs against some 500 targets (1) (although this totemic figure is probably overestimated and the real number is likely to be as low as 270 according to a persuasive presentation by Inpharmatica at the SMI Proteomics Conference in January this year). The second factor was the calculation that the human genome of 100,000 genes might yield some 5,000 to 10,000 drug targets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Gareth Roberts, Co-Founder, and Jonathan Swinton, Bioinformatics Researcher at Proteom

Gareth Roberts' career to date has evolved from postdoctoral research in the field of neuropsychiatric disorders with the Medical Research Council, to building and leading a 10-strong team within Imperial College School of Medicine and as a Group Director of a discovery department with SmithKline Beecham Pharmaceuticals.

During the course of these activities Gareth has published over 145 articles in refereed journals, written or edited six books, filed over 30 patent applications (six granted to date), gained an MBA and has been elected a Fellow of the Royal Society of Arts. He is a Co-Founder of two biotechnology companies active in the area of pharmacogenetics and genetic profiling (SCIONA Ltd.), and bioinformatics/proteomics (PROTEOM founded 1999).

Jonathan Swinton trained as a mathematician at Cambridge University, UK and received a PhD in Applied Mathematics from Imperial College London in 1990. Since then he has conducted research and has taught mathematical immunology, epidemiology and ecology in London, Oxford and Cambridge.

He now works as a Bioinformatics Researcher at Proteom, using machine learning and data mining techniques to understand protein-peptide interactions.
spacer
Gareth Roberts
spacer
spacer
spacer
Jonathan Swinton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cambridge Sensotec (manufacturers of Dynascan) obtains new ISO accreditation

On the 30th May 2019, Cambridge Sensotec proudly achieved ISO 9001:2015 accreditation under the BSI (British Standards Institution). Cambridge Sensotec Ltd now joins 1.3 million companies across 112 countries worldwide that hold this prestigious certificate.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement